IP Library Granted Patent US 8,808,754
Granted Patent B2
US 8,808,754 · App. 11/477,307 · Granted Aug 19, 2014

Methods for the treatment of wounds

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,808,754
App. No.
11/477,307
Granted
Aug 19, 2014
Kind
B2
Abstract

A method of treatment of a wound, said method comprising the step of injecting an effective amount of an oxygen-containing fluid into said wound at a location below a surface of said wound, said step of injecting being carried out through a conduit having one or more outlets for said fluid, wherein substantially all of said outlets are positioned below the surface of the wound during said step of injecting. Injection of oxygen directly into the wound tissue below the wound surface provides enhanced wound healing.

Claims (17)

1. A method of treatment of a wound, said method comprising the step of injecting an effective amount of an oxygen-containing fluid selectively and directly into a layer of wound tissue located below a surface layer of said wound, said step of injecting being carried out through a conduit having one or more outlets for said fluid, wherein all of said outlets are positioned below the surface of the wound during said step of injecting, and wherein pressure and delivery rate of the injection are adjusted to prevent the formation of a bolus of liquid or gas inside the wound.

2. The method of claim 1 , wherein the oxygen-containing fluid is a liquid containing dissolved oxygen.

3. The method of claim 2 , wherein the liquid is water and the oxygen is dissolved therein in an amount greater than about 10 mg per liter.

4. The method of claim 1 , wherein the oxygen-containing fluid is an oxygen-containing gas.

5. The method of claim 4 , wherein the partial pressure of oxygen in said gas is greater than about 0.25 bar.

6. The method of claim 1 , wherein the step of injecting is performed in continuous fashion for a period of from about 1 hour to about 30 days.

7. A method of treatment of a wound according to claim 1 , wherein the conduit is configured to deliver the oxygen-containing fluid below a surface necrotic tissue layer of the wound.

8. A method of treatment of a wound according to claim 1 , wherein the conduit is configured to deliver the oxygen into or onto a granulation tissue in the wound.

9. A method of treatment of a wound according to claim 1 , wherein the wound is a chronic wound.

10. A method of treatment of a wound according to claim 1 . wherein the conduit is formed from a microcatheter or a syringe.

11. A method of treatment of a wound according to claim 1 , wherein at least a part of the conduit is bioabsorbabale.

12. A method of treatment of a wound according to claim 1 , wherein the method does not comprise damage to tissue surrounding the wound.

13. A method of treatment of a wound according to claim 1 , wherein the conduit has an effective lumen diameter of less than about 75 micrometers.

14. A method of treatment of a wound according to claim 1 , wherein the oxygen containing fluid is supplied to the conduit at elevated pressure.

15. The method of claim 1 wherein the step of injecting is performed in continuous fashion for a period of from about 1 day to about 14 days.

16. A method of treatment of a wound according to claim 1 , wherein the method does not comprise damage to tissue surrounding the wound by suturing.

17. A Method of treatment of a wound, said method comprising the step of injecting an effective amount of an oxygen-containing fluid selectively and directly into a layer of wound tissue located below a surface layer of said wound, said step of injecting being carried out through a conduit having one or more outlets for said fluid, wherein all of said outlets are positioned below the surface of the wound during said step of injecting, and wherein the conduit is configured to deliver the oxygen-containing fluid below a surface necrotic tissue layer of the wound.

Assignments (13)
RELEASE OF SECURITY INTEREST IN PATENTS Recorded Nov 7, 2019
From: WILMINGTON TRUST, NATIONAL ASSOCIATION
To: KCI USA, INC.; KCI LICENSING, INC.
Reel/Frame 050966/0547 →
RELEASE OF SECURITY INTEREST IN PATENTS Recorded Nov 6, 2019
From: WILMINGTON TRUST, NATIONAL ASSOCIATION
To: KINETIC CONCEPTS, INC.; KCI USA, INC.; ACELITY L.P. INC.; CHIRON HOLDINGS, INC.; CHIRON TOPCO, INC.; KCI ANIMAL HEALTH, LLC; KCI HOLDING COMPANY, INC.; KCI HOMECARE, INC.; KCI IMPORTS, INC.; KCI INTERNATIONAL, INC.; KCI LICENSING, INC.; KCI PROPERTIES LIMITED; KCI REAL HOLDINGS, L.L.C.; KCI REAL PROPERTY LIMITED; KCI USA REAL HOLDINGS, L.L.C.; TECHNIMOTION, LLC
Reel/Frame 050945/0278 →
RELEASE OF SECURITY INTEREST Recorded Oct 11, 2019
From: BANK OF AMERICA, N.A.
To: KCI USA, INC.
Reel/Frame 050710/0955 →
RELEASE OF SECURITY INTEREST REEL/FRAME 040098/0268 Recorded Feb 8, 2017
From: WILMINGTON TRUST
To: KCI USA, INC.
Reel/Frame 041666/0320 →
SECURITY AGREEMENT Recorded Feb 7, 2017
From: KCI USA, INC., AS GRANTOR
To: BANK OF AMERICA, N.A., AS COLLATERAL AGENT
Reel/Frame 041650/0013 →
RELEASE OF SECURITY INTEREST IN INTELLECTUAL PROPERTY Recorded Feb 6, 2017
From: BANK OF AMERICA, N.A., AS COLLATERAL AGENT
To: KCI LICENSING, INC., AS GRANTOR; TECHNIMOTION, LLC, A DELAWARE LIMITED LIABILITY COMPANY, AS GRANTOR; SYSTAGENIX WOUND MANAGEMENT (US), INC., A DELAWARE CORPORATION, AS GRANTOR
Reel/Frame 041395/0044 →
LIMITED THIRD LIEN INTELLECTUAL PROPERTY SECURITY AGREEMENT Recorded Oct 7, 2016
From: KCI USA, INC.; LIFECELL CORPORATION; KCI LICENSING, INC.
To: WILMINGTON TRUST, NATIONAL ASSOCIATION, AS COLLATERAL AGENT
Reel/Frame 040291/0237 →
SECOND LIEN SECURITY AGREEMENT Recorded Sep 21, 2016
From: KCI USA, INC.; LIFECELL CORPORATION; KCI LICENSING, INC.
To: WILMINGTON TRUST, NATIONAL ASSOCIATION, AS COLLATERAL AGENT
Reel/Frame 040098/0268 →
SECURITY INTEREST Recorded Feb 17, 2016
From: KINETIC CONCEPTS, INC.; KCI USA, INC.; ACELITY L.P. INC.; CHIRON HOLDINGS, INC.; CHIRON TOPCO, INC.; KCI ANIMAL HEALTH, LLC; KCI HOLDING COMPANY, INC.; KCI HOMECARE, INC.; KCI IMPORTS, INC.; KCI INTERNATIONAL, INC.; KCI LICENSING, INC.; KCI PROPERTIES LIMITED; KCI REAL HOLDINGS, L.L.C.; KCI REAL PROPERTY LIMITED; KCI USA REAL HOLDINGS, L.L.C.; LIFECELL CORPORATION; TECHNIMOTION, LLC
To: WILMINGTON TRUST, NATIONAL ASSOCIATION
Reel/Frame 037845/0497 →
MERGER AND CHANGE OF NAME Recorded May 11, 2015
From: SYSTAGENIX WOUND MANAGEMENT (US),INC.; KCI USA, INC.
To: KCI USA, INC.
Reel/Frame 035645/0178 →
MERGER AND CHANGE OF NAME Recorded Feb 11, 2015
From: SYSTAGENIX WOUND MANAGEMENT (US), INC.; KCI USA, INC.
To: KCI USA, INC.
Reel/Frame 034954/0870 →
SECURITY AGREEMENT Recorded Oct 29, 2013
From: SYSTAGENIX WOUND MANAGEMENT (US), INC.
To: BANK OF AMERICA, N.A., AS COLLATERAL AGENT
Reel/Frame 031508/0011 →
RELEASE OF SECURITY INTEREST Recorded Oct 28, 2013
From: J.P. MORGAN EUROPE LIMITED
To: SYSTAGENIX WOUND MANAGEMENT (US), INC.
Reel/Frame 031506/0186 →